Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Ying–Hong Shi(Ministry of Education of the People's Republic of China), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University), Jianbing Wu(Nanchang University), Ming Huang, Ying Cheng(Jilin Province Tumor Hospital), Weidong Jia(Anhui Provincial Hospital), Tsang-En Wang(Mackay Memorial Hospital), Jens Samol(Tan Tock Seng Hospital), Jian Zhou(Sun Yat-sen University), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Mingjun Zhang(Anhui Medical University), Xiangdong Hua(Liaoning Cancer Hospital & Institute), Jinfang Zheng(Hainan General Hospital), Y. Li(Nanchang University), Fuxiang Zhou(Wuhan University), Guohong Han(Xijing Hospital), Hong-Tao Hu(Henan Cancer Hospital), Weiwen Su(Changhua Christian Hospital), Ledu Zhou(Central South University), Xiangcai Wang(First Affiliated Hospital of Gannan Medical University), Yuxian Bai(Harbin Medical University), Yilei Mao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shanzhi Gu(Hunan Cancer Hospital), Bixiang Zhang(Ministry of Education of the People's Republic of China), Hongming Liu(Army Medical University), Tao Zhang(Sun Yat-sen University), Feng Zhang(Hubei Cancer Hospital), Jie Shen(Nanjing Drum Tower Hospital), Wenhua Zhang(Qilu Hospital of Shandong University), Wu Zhang(Huawei Technologies (China)), Zhiyu Chen(Shanghai Medical College of Fudan University), Sheng Hu(Hubei Cancer Hospital), Guoping Zhang(Shantou University), Bingfeng Shao(Nantong Tumor Hospital), Yunfeng Shan(Wenzhou Medical University), Hui Zeng(Zhejiang Cancer Hospital), Yajin Chen(Sun Yat-sen University), Tianfu Wen(Sichuan University), Chengyou Du(The Affiliated Yongchuan Hospital of Chongqing Medical University), Cheng-Wu Zhang(Zhejiang Provincial People's Hospital), Yifu He(Anhui Provincial Hospital), Rui Wang(First Affiliated Hospital of Bengbu Medical College), Yan Shen(First Affiliated Hospital Zhejiang University), Xuetao Shi(Shandong Tumor Hospital), Yongdong Jin(Sichuan Cancer Hospital), Yabing Guo(Nanfang Hospital), Shunli Shen(Sun Yat-sen University), Bo Liang(Changchun 208 Hospital), Wenzhi Guo(First Affiliated Hospital of Zhengzhou University)
˜The œLancet. Gastroenterology & hepatology
May 20, 2025
10.1016/s2468-1253(25)00059-7
Cited by 39

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|The Lancet|2023|461
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436